Pharmacokinetic analysis of the microscopic distribution of enzyme-conjugated antibodies and prodrugs: comparison with experimental data
- PMID: 8595158
- PMCID: PMC2074453
- DOI: 10.1038/bjc.1996.80
Pharmacokinetic analysis of the microscopic distribution of enzyme-conjugated antibodies and prodrugs: comparison with experimental data
Abstract
A mathematical model was developed to improve understanding of the biodistribution and microscopic profiles of drugs and prodrugs in a system using enzyme-conjugated antibodies as part of a two-step method for cancer treatment. The use of monoclonal antibodies alone may lead to heterogeneous uptake within the tumour tissue; the use of a second, low molecular weight agent may provide greater penetration into tumour tissue. This mathematical model was used to describe concentration profiles surrounding individual blood vessels within a tumour. From these profiles the area under the curve and specificity ratios were determined. By integrating these results spatially, average tissue concentrations were determined and compared with experimental results from three different systems in the literature; two using murine antibodies and one using humanised fusion proteins. The maximum enzyme conversion rate (Vmax) and the residual antibody concentration in the plasma and normal tissue were seen to be key determinants of drug concentration and drug-prodrug ratios in the tumour and other organs. Thus, longer time delays between the two injections, clearing the antibody from the blood stream and the use of 'weaker' enzymes (lower Vmax) will be important factors in improving this prodrug approach. Of these, the model found the effective clearance of the antibody outside of the tumour to be the most effective. The use of enzyme-conjugated antibodies may offer the following advantages over the bifunctional antibody-hapten system: (i) more uniform distribution of the active agent; (ii) higher concentrations possible for the active agent; and (iii) greater specificity (therapeutic index).
Similar articles
-
Pharmacokinetic analysis of two-step approaches using bifunctional and enzyme-conjugated antibodies.Cancer Res. 1991 Jun 15;51(12):3119-30. Cancer Res. 1991. PMID: 2039991
-
Systems biology and the mathematical modelling of antibody-directed enzyme prodrug therapy (ADEPT).Syst Biol (Stevenage). 2005 Dec;152(4):291-302. doi: 10.1049/ip-syb:20050047. Syst Biol (Stevenage). 2005. PMID: 16986273
-
Plasma clearance of an antibody--enzyme conjugate in ADEPT by monoclonal anti-enzyme: its effect on prodrug activation in vivo.Br J Cancer. 1995 Dec;72(6):1357-63. doi: 10.1038/bjc.1995.515. Br J Cancer. 1995. PMID: 8519645 Free PMC article.
-
Tumor targeting: activation of prodrugs by enzyme-monoclonal antibody conjugates.Trends Biotechnol. 1994 Jun;12(6):234-9. doi: 10.1016/0167-7799(94)90122-8. Trends Biotechnol. 1994. PMID: 7765070 Review.
-
Antitumour prodrug development using cytochrome P450 (CYP) mediated activation.Anticancer Drug Des. 1999 Dec;14(6):473-86. Anticancer Drug Des. 1999. PMID: 10834269 Review.
Cited by
-
Modeling the dynamics of antibody-target binding in living tumors.Sci Rep. 2020 Oct 7;10(1):16764. doi: 10.1038/s41598-020-73711-y. Sci Rep. 2020. PMID: 33028895 Free PMC article.
-
Towards Optimal Design of Cancer Nanomedicines: Multi-stage Nanoparticles for the Treatment of Solid Tumors.Ann Biomed Eng. 2015 Sep;43(9):2291-300. doi: 10.1007/s10439-015-1276-9. Epub 2015 Feb 11. Ann Biomed Eng. 2015. PMID: 25670323 Free PMC article.
-
Mathematical and experimental analysis of localization of anti-tumour antibody-enzyme conjugates.Br J Cancer. 1999 Aug;80(11):1747-53. doi: 10.1038/sj.bjc.6690592. Br J Cancer. 1999. PMID: 10468291 Free PMC article.
-
Delivery of molecular and cellular medicine to solid tumors.Adv Drug Deliv Rev. 2012 Dec 1;64(Suppl):353-365. doi: 10.1016/j.addr.2012.09.011. Adv Drug Deliv Rev. 2012. PMID: 24511174 Free PMC article.
-
Molecular Simulation of Receptor Occupancy and Tumor Penetration of an Antibody and Smaller Scaffolds: Application to Molecular Imaging.Mol Imaging Biol. 2017 Oct;19(5):656-664. doi: 10.1007/s11307-016-1041-y. Mol Imaging Biol. 2017. PMID: 28213834
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources